Magali Le Garff-Tavernier
0000-0002-3131-3240
3 papers found
Refreshing results…
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma
Missing publications? Search for publications with a matching author name.